Table 1.
Baseline patient characteristics (n = 231) and treatment regimen started at the inclusion visit
| Women, n (%) | 162 (70·1) |
| Mean age (years ± s.d.) | 57·4 ± 13·0 |
| Rheumatoid factor‐positive, n (%) | 150 (64·9) |
| IgG anti‐CCP‐positive, n (%) | 172 (74·4) |
| DAS28 (mean ± s.d.)a | 5·1 ± 1·2 |
| HAQ (mean ± s.d.)b | 1·0 ± 0·6 |
| Mean IgG anti‐CCP level (U/ml ± s.e.m.)c | 180·2 ± 9·7 |
| Mean IgA anti‐CCP level (µg/ml ± s.e.m.)d | 7·5 ± 0·9 |
| Mean IgM anti‐CCP level (AU/ml ± s.e.m.)e | 9950·2 ± 1262 |
| Mean SIgA anti‐CCP level (AU/ml ± s.e.m.)f | 3929·4 ± 389·7 |
| Oral corticosteroids, n (%)h | 138 (59·7) |
| csDMARD single therapy, n (%) | 196 (84·8) |
| csDMARD combination therapy, n (%) | 20 (8·7) |
| bDMARD therapy, n (%) | 1 (0·4) |
DAS28 = disease activity score 28; HAQ = health assessment questionnaire; csDMARD = conventional synthetic disease‐modifying anti‐rheumatic drug (single therapy including methotrexate (MTX), salazopyrin (SSZ), anti‐malaria or leflunomide. Combination therapy including different combinations of MTX, SSZ, anti‐malarial and imurel) and bDMARD = biological disease‐modifying anti‐rheumatic drug; s.e.m. = standard error of the mean.
Data available from 215 patients;
data available from 206 patients;
cut‐off: ACPA IgG 7U/ml;
anti‐citrullinated protein antibodies (ACPA) immunoglobulin (Ig)A 2 µg/l;
ACPA IgM 6032 AU/ml;
ACPA SIgA 3089 AU/ml;
data available from 230 patients.